NYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis $15.81 +0.83 (+5.54%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$15.08▼$15.9150-Day Range$13.84▼$17.2352-Week Range$12.95▼$25.47Volume433,942 shsAverage Volume758,928 shsMarket Capitalization$1.44 billionP/E RatioN/ADividend YieldN/APrice Target$38.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arcus Biosciences alerts: Email Address Arcus Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside141.1% Upside$38.11 Price TargetShort InterestBearish13.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.07) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 starsMedical Sector459th out of 936 stocksPharmaceutical Preparations Industry211th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArcus Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcus Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.76% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Arcus Biosciences has recently increased by 7.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RCUS. Previous Next 3.1 News and Social Media Coverage News SentimentArcus Biosciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arcus Biosciences this week, compared to 3 articles on an average week.Search Interest5 people have searched for RCUS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows3 people have added Arcus Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcus Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcus Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Arcus Biosciences Stock (NYSE:RCUS)Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Read More RCUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCUS Stock News HeadlinesJuly 26 at 6:06 AM | finance.yahoo.comArcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline UpdateJuly 22, 2024 | finanznachrichten.deBiosimilar Market to Surpass $102.68 Billion by 2034 with 8.9% Annual Growth, Says Fact.MRJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 21, 2024 | americanbankingnews.comArcus Biosciences (NYSE:RCUS) versus Emmaus Life Sciences (OTCMKTS:EMMA) Financial ContrastJune 25, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsJune 11, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsJune 10, 2024 | businesswire.comArcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI CancersJune 2, 2024 | businesswire.comZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated ComputingJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 2, 2024 | businesswire.comGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerJune 2, 2024 | businesswire.comGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerJune 1, 2024 | businesswire.comGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersJune 1, 2024 | businesswire.comGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersMay 24, 2024 | businesswire.comArcus Biosciences Announces New Employment Inducement GrantsMay 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market PotentialMay 15, 2024 | markets.businessinsider.comBuy Rating on Arcus Biosciences: Unique Anti-TIGIT Antibody and Promising Cancer Trials Fuel OptimismMay 15, 2024 | seekingalpha.comArcus Biosciences: A Preview Of Their Outlook Ahead Of ASCOMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Arcus Biosciences Based on Promising Efficacy and Safety Profile of DomvanalimabSee More Headlines Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:RCUS CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees500Year FoundedN/APrice Target and Rating Average Stock Price Target$38.11 High Stock Price Target$70.00 Low Stock Price Target$23.00 Potential Upside/Downside+141.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-307,000,000.00 Net Margins-97.47% Pretax Margin-95.78% Return on Equity-40.98% Return on Assets-19.25% Debt Debt-to-Equity RatioN/A Current Ratio5.22 Quick Ratio5.22 Sales & Book Value Annual Sales$117 million Price / Sales12.29 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book2.56Miscellaneous Outstanding Shares90,950,000Free Float79,766,000Market Cap$1.44 billion OptionableOptionable Beta0.90 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Terry J. Rosen Ph.D. (Age 64)Co-Founder, Chairman & CEO Comp: $756.11kDr. Juan Carlos Jaen Ph.D. (Age 66)Co- Founder & President Comp: $931.14kMr. Robert C. Goeltz II (Age 51)Principal Financial Officer & CFO Comp: $745.29kMs. Jennifer A. Jarrett M.B.A. (Age 53)Chief Operating Officer Comp: $925.29kDr. Dimitry S.A. Nuyten M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $700.34kDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory BoardMr. Alexander Azoy (Age 48)VP of Finance & Principal Accounting Officer Dr. Jonathan Yingling Ph.D. (Age 55)Chief Scientific Officer More ExecutivesKey CompetitorsApellis PharmaceuticalsNASDAQ:APLSAvidity BiosciencesNASDAQ:RNACrinetics PharmaceuticalsNASDAQ:CRNXImmunovantNASDAQ:IMVTArcellxNASDAQ:ACLXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 4,303 shares on 7/26/2024Ownership: 0.435%Louisiana State Employees Retirement SystemBought 700 shares on 7/24/2024Ownership: 0.030%Diversified Trust CoBought 1,467 shares on 7/16/2024Ownership: 0.015%SG Americas Securities LLCBought 120,650 shares on 7/12/2024Ownership: 0.142%Comerica BankSold 2,754 shares on 5/17/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions RCUS Stock Analysis - Frequently Asked Questions How have RCUS shares performed this year? Arcus Biosciences' stock was trading at $19.10 at the beginning of 2024. Since then, RCUS shares have decreased by 17.2% and is now trading at $15.81. View the best growth stocks for 2024 here. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) posted its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.92. The business's quarterly revenue was up 480.0% on a year-over-year basis. What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO? 4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Top institutional investors of Arcus Biosciences include Bank of New York Mellon Corp (0.44%), SG Americas Securities LLC (0.14%), Louisiana State Employees Retirement System (0.03%) and Diversified Trust Co (0.01%). Insiders that own company stock include Gilead Sciences, Inc, Juan C Jaen, Terry J Rosen, Jennifer Jarrett, Robert C Goeltz II, Carolyn C Tang and Alexander Azoy. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Gilead Sciences (GILD). This page (NYSE:RCUS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
